<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848899</url>
  </required_header>
  <id_info>
    <org_study_id>12-02409</org_study_id>
    <nct_id>NCT01848899</nct_id>
  </id_info>
  <brief_title>Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography</brief_title>
  <official_title>The Assesment of Thrombotic Markers Utilizing Ionic Versus Non-Ionic Contrast During Coronary Angiography and Intervention (AToMIC) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine how two different types of iodinated contrast media
      (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific
      markers of thrombogenesis and platelet function in patients undergoing coronary angiography,
      and if the use of bivalirudin, a direct thrombin inhibitor used during percutaneous coronary
      intervention (PCI), affects any contrast-related changes in thrombogenesis and platelet
      function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin Generation Test: Baseline</measure>
    <time_frame>baseline</time_frame>
    <description>The thrombin generation test uses recombinant tissue factor as a stimulus to initiate thrombin generation in plasma samples. The outcome from this assay is reported as area under the curve and represents the amount of thrombin in each sample. The curve is created by measuring the generated thrombin every 20 seconds from 0 to 95 minutes post stimulus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombin Generation Test: After Coronary Angiography</measure>
    <time_frame>1 hour</time_frame>
    <description>The thrombin generation test uses recombinant tissue factor as a stimulus to initiate thrombin generation in plasma samples. The outcome from this assay is reported as area under the curve and represents the amount of thrombin in each sample. The curve is created by measuring the generated thrombin every 20 seconds from 0 to 95 minutes post stimulus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Maximal Platelet Aggregation: Epinephrine</measure>
    <time_frame>Baseline to 1 hour</time_frame>
    <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 10 μM epinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Maximal Platelet Aggregation: Arachidonic Acid</measure>
    <time_frame>1 hour</time_frame>
    <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 1600 μM arachidonic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Maximal Platelet Aggregation: ADP</measure>
    <time_frame>1 hour</time_frame>
    <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 20 μM of ADP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ioxaglate Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Iodixanol arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol</intervention_name>
    <description>contrast media used during coronary angiography</description>
    <arm_group_label>Iodixanol arm</arm_group_label>
    <other_name>Visipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ioxaglate</intervention_name>
    <description>contrast media used during coronary angiography</description>
    <arm_group_label>Ioxaglate Arm</arm_group_label>
    <other_name>Hexabrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>A direct thrombin inhibitor</description>
    <arm_group_label>Ioxaglate Arm</arm_group_label>
    <arm_group_label>Iodixanol arm</arm_group_label>
    <other_name>Angiomax</other_name>
    <other_name>Angiox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be more than 18 years of age

          -  referred for coronary angiography and on dual anti-platelet therapy (aspirin and
             clopidogrel).

        Exclusion Criteria:

          -  on warfarin

          -  on low molecular weight heparin within 12 hours of coronary angiography or
             unfractionated heparin with activated clotting time &gt;150 at time of procedure -on
             cilostazol

          -  on persantine

          -  on non- steroidal anti-inflammatory medications (ibuprofen/motrin/advil,
             naproxen/aleve, indomethacin, sulindac, etodolac, diclofenac, celecoxib) within 72
             hours of procedure

          -  on prasugrel (not an exclusion criteria for ST-segment elevation myocardial infarction
             registry

          -  undergoing coronary angiography via radial access

          -  undergoing planned diagnostic coronary angiography only

          -  unable to tolerate dual anti-platelet therapy

          -  with known allergy to CM

          -  received CM within 24 hours of coronary angiography

          -  on dialysis

          -  do not consent or are unable to give consent

          -  are participating in another competing study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Feit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Binita Shah, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <results_first_submitted>January 29, 2016</results_first_submitted>
  <results_first_submitted_qc>March 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2016</results_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary angiography</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Contrast media</keyword>
  <keyword>Platelet activity</keyword>
  <keyword>Thrombin generation</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ioxaglate Arm</title>
          <description>Ioxaglate: contrast media used during coronary angiography</description>
        </group>
        <group group_id="P2">
          <title>Iodixanol Arm</title>
          <description>Iodixanol: contrast media used during coronary angiography</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ioxaglate Arm</title>
          <description>Ioxaglate: contrast media used during coronary angiography</description>
        </group>
        <group group_id="B2">
          <title>Iodixanol Arm</title>
          <description>Iodixanol: contrast media used during coronary angiography</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thrombin Generation Test: Baseline</title>
        <description>The thrombin generation test uses recombinant tissue factor as a stimulus to initiate thrombin generation in plasma samples. The outcome from this assay is reported as area under the curve and represents the amount of thrombin in each sample. The curve is created by measuring the generated thrombin every 20 seconds from 0 to 95 minutes post stimulus.</description>
        <time_frame>baseline</time_frame>
        <population>A valid thrombogram was generated post-diagnostic angiography in 43/50 participants in the Ioxaglate arm and 37/50 participants in the Iodixanol arm. Thus, not all 100 participants were able to be included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioxaglate Arm</title>
            <description>Ioxaglate: contrast media used during coronary angiography</description>
          </group>
          <group group_id="O2">
            <title>Iodixanol Arm</title>
            <description>Iodixanol: contrast media used during coronary angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombin Generation Test: Baseline</title>
          <description>The thrombin generation test uses recombinant tissue factor as a stimulus to initiate thrombin generation in plasma samples. The outcome from this assay is reported as area under the curve and represents the amount of thrombin in each sample. The curve is created by measuring the generated thrombin every 20 seconds from 0 to 95 minutes post stimulus.</description>
          <population>A valid thrombogram was generated post-diagnostic angiography in 43/50 participants in the Ioxaglate arm and 37/50 participants in the Iodixanol arm. Thus, not all 100 participants were able to be included in analysis.</population>
          <units>nM*minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1810" lower_limit="1540" upper_limit="2089"/>
                    <measurement group_id="O2" value="1682" lower_limit="1534" upper_limit="2147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Maximal Platelet Aggregation: Epinephrine</title>
        <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 10 μM epinephrine</description>
        <time_frame>Baseline to 1 hour</time_frame>
        <population>Sufficient volumes of blood were not available for all participants to perform the analyses required for some secondary outcomes. Thus, not all 100 participants are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioxaglate Arm</title>
            <description>Ioxaglate: contrast media used during coronary angiography</description>
          </group>
          <group group_id="O2">
            <title>Iodixanol Arm</title>
            <description>Iodixanol: contrast media used during coronary angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Maximal Platelet Aggregation: Epinephrine</title>
          <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 10 μM epinephrine</description>
          <population>Sufficient volumes of blood were not available for all participants to perform the analyses required for some secondary outcomes. Thus, not all 100 participants are included in this outcome measure.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="-8.2" upper_limit="27.0"/>
                    <measurement group_id="O2" value="25.7" lower_limit=".9" upper_limit="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Maximal Platelet Aggregation: Arachidonic Acid</title>
        <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 1600 μM arachidonic acid</description>
        <time_frame>1 hour</time_frame>
        <population>Sufficient volumes of blood were not available for all participants to perform the analyses required for some secondary outcomes. Thus, not all 100 participants are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioxaglate Arm</title>
            <description>Ioxaglate: contrast media used during coronary angiography</description>
          </group>
          <group group_id="O2">
            <title>Iodixanol Arm</title>
            <description>Iodixanol: contrast media used during coronary angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Maximal Platelet Aggregation: Arachidonic Acid</title>
          <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 1600 μM arachidonic acid</description>
          <population>Sufficient volumes of blood were not available for all participants to perform the analyses required for some secondary outcomes. Thus, not all 100 participants are included in this outcome measure.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="10.7" upper_limit="74.3"/>
                    <measurement group_id="O2" value="36.0" lower_limit="4.4" upper_limit="109.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Maximal Platelet Aggregation: ADP</title>
        <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 20 μM of ADP</description>
        <time_frame>1 hour</time_frame>
        <population>Sufficient volumes of blood were not available for all participants to perform the analyses required for some secondary outcomes. Thus, not all 100 participants are included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioxaglate Arm</title>
            <description>Ioxaglate: contrast media used during coronary angiography</description>
          </group>
          <group group_id="O2">
            <title>Iodixanol Arm</title>
            <description>Iodixanol: contrast media used during coronary angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Maximal Platelet Aggregation: ADP</title>
          <description>Percent change in maximal platelet aggregation from pre- to post-contrast in response to 20 μM of ADP</description>
          <population>Sufficient volumes of blood were not available for all participants to perform the analyses required for some secondary outcomes. Thus, not all 100 participants are included in this outcome measure.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-8.4" upper_limit="1.7"/>
                    <measurement group_id="O2" value=".05" lower_limit="-5.9" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Thrombin Generation Test: After Coronary Angiography</title>
        <description>The thrombin generation test uses recombinant tissue factor as a stimulus to initiate thrombin generation in plasma samples. The outcome from this assay is reported as area under the curve and represents the amount of thrombin in each sample. The curve is created by measuring the generated thrombin every 20 seconds from 0 to 95 minutes post stimulus.</description>
        <time_frame>1 hour</time_frame>
        <population>A valid thrombogram was generated post-diagnostic angiography in 43/50 participants in the Ioxaglate arm and 37/50 participants in the Iodixanol arm. Thus, not all 100 participants were able to be included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ioxaglate Arm</title>
            <description>Ioxaglate: contrast media used during coronary angiography</description>
          </group>
          <group group_id="O2">
            <title>Iodixanol Arm</title>
            <description>Iodixanol: contrast media used during coronary angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombin Generation Test: After Coronary Angiography</title>
          <description>The thrombin generation test uses recombinant tissue factor as a stimulus to initiate thrombin generation in plasma samples. The outcome from this assay is reported as area under the curve and represents the amount of thrombin in each sample. The curve is created by measuring the generated thrombin every 20 seconds from 0 to 95 minutes post stimulus.</description>
          <population>A valid thrombogram was generated post-diagnostic angiography in 43/50 participants in the Ioxaglate arm and 37/50 participants in the Iodixanol arm. Thus, not all 100 participants were able to be included in analysis.</population>
          <units>nM*minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649" lower_limit="314" upper_limit="1347"/>
                    <measurement group_id="O2" value="681" lower_limit="229" upper_limit="1237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ioxaglate Arm</title>
          <description>Ioxaglate: contrast media used during coronary angiography</description>
        </group>
        <group group_id="E2">
          <title>Iodixanol Arm</title>
          <description>Iodixanol: contrast media used during coronary angiography</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hives/rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Binita Shah</name_or_title>
      <organization>NYU Langone Medical Center</organization>
      <phone>212-263-4235</phone>
      <email>binita.shah@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

